IntegraGen Announces Collaboration with the (IFCT) to Explore the Role of miR-31-3p Biomarker in Non-Small Cell Lung Cancer.
IntegraGen, a French leader in genomics services also specializing in the development of molecular diagnostic tests for oncology and autism, today announced a collaboration with the (IFCT) to explore the role of its proprietary miR-31-3p biomarker in advanced stage non-small cell lung cancer (NSCLC). The study aims to identify whether the expression of the microRNA miR-31-3p is correlated with outcomes associated with the use of (EGFR) targeted therapies for lepidic adenocarcinomas of the lung.